TY - JOUR
T1 - Updates on Non-Statin LDL-Lowering Therapy
AU - Abdulla, Amer
AU - Shalaby, Mostafa
AU - Kumfa, Paul
AU - Raja, Muhammad
AU - Allencherril, Joseph
AU - Sharifeh, Tareq Abu
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.
PY - 2024
Y1 - 2024
N2 - Purpose of Review: There is ample evidence of the benefits and safety of low-density lipoprotein (LDL)-lowering therapies in the prevention of atherosclerotic cardiovascular disease. While statins remain the first-line agent for LDL reduction, several new therapies are now available. This narrative review provides an overview of currently available non-statin LDL-lowering agents, specifically mechanisms of action and data on efficacy and safety. It also discusses recommendations on their use in clinical practice. Recent Findings: Ezetimibe, PCSK9 inhibitors, and bempedoic acid have proven safe and efficacious in reducing cardiovascular events in large randomized controlled trials. Inclisiran is a promising agent that suppresses PCSK9 mRNA translation and is currently under investigation in a large clinical outcomes randomized controlled trial assessing its effect on clinical outcomes. Summary: Expert consensus advocates for lower LDL targets in higher risk patients and escalation to or a combination of non-statin therapies as needed to achieve these goals.
AB - Purpose of Review: There is ample evidence of the benefits and safety of low-density lipoprotein (LDL)-lowering therapies in the prevention of atherosclerotic cardiovascular disease. While statins remain the first-line agent for LDL reduction, several new therapies are now available. This narrative review provides an overview of currently available non-statin LDL-lowering agents, specifically mechanisms of action and data on efficacy and safety. It also discusses recommendations on their use in clinical practice. Recent Findings: Ezetimibe, PCSK9 inhibitors, and bempedoic acid have proven safe and efficacious in reducing cardiovascular events in large randomized controlled trials. Inclisiran is a promising agent that suppresses PCSK9 mRNA translation and is currently under investigation in a large clinical outcomes randomized controlled trial assessing its effect on clinical outcomes. Summary: Expert consensus advocates for lower LDL targets in higher risk patients and escalation to or a combination of non-statin therapies as needed to achieve these goals.
KW - Bempedoic acid
KW - Ezetimibe
KW - Hyperlipidemia
KW - Inclisiran
KW - Low-density lipoprotein
KW - Proprotein convertase subtilisin/kexin type 9 inhibitor
UR - http://www.scopus.com/inward/record.url?scp=85186592870&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85186592870&partnerID=8YFLogxK
U2 - 10.1007/s11886-024-02028-3
DO - 10.1007/s11886-024-02028-3
M3 - Article
C2 - 38436784
AN - SCOPUS:85186592870
SN - 1523-3782
JO - Current Cardiology Reports
JF - Current Cardiology Reports
ER -